IDT Australia Ltd (ASX: IDT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

IDT Australia Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $33.74 million
P/E Ratio 15.55
Dividend Yield N/A
Shares Outstanding 240.87 million
Earnings per share 0.009
Dividend per share N/A
Year To Date Return -45.10%
Earnings Yield 6.43%
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

IDT Australia Ltd (ASX: IDT)
Latest News

A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
Healthcare Shares

How did ASX biotech shares perform in FY22?

Biotech certainly wasn't immune to market pressures in FY22.

Read more »

A woman screams and holds her hands up in frustration.
Healthcare Shares

Why the IDT Australia (ASX:IDT) share price is crashing 37% lower today

IDT shares are being hammered today...

Read more »

a medical person in full protective clothing holds a tray of Covid-19 vaccinations amid a haze caused by cold and ice.
Healthcare Shares

Why is the IDT (ASX:IDT) share price halted today?

Trading in the pharmaceutical manufacturer is on hold pending an announcement.

Read more »

asx share price swing represented by old lady on swing
Healthcare Shares

IDT (ASX:IDT) share price swings as CEO lauds mRNA tech in fight against Omicron

Vaccine manufacturers are racing to get ahead of the fast-mutating coronavirus.

Read more »

Starpharma share price A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies
Share Market News

The Starpharma (ASX: SPL) share price surges on Vietnam launch

The Starpharma Holdings Limited (ASX: SPL) share price is racing ahead this morning after confirming its antiviral nasal spray will…

Read more »

A drawing of a white rocket streaking up, indicating a surging share pirce movement
Healthcare Shares

IDT Australia (ASX:IDT) share price rockets 40% on COVID vaccine update

What did IDT Australia update the ASX with?

Read more »

a medical researcher holds a vial of vaccine with a needle inserted in the top watching intently behind a mask and goggles and protective medical clothing.
Share Gainers

Here’s why the IDT Australia (ASX:IDT) share price is up 75% in a month.

IDT shares have soared well into the green over the last month.

Read more »

A drawing of a rocket follows a chart up, indicating share price lift
Share Gainers

IDT Australia (ASX: IDT) share price surges 16% on vaccine government talks

IDT shares are well on the move this morning after a key update.

Read more »

IDT ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About IDT Australia Ltd

IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services.

IDT Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
16 Aug 2022 $0.14 $0.00 0.00% 196,924 $0.15 $0.15 $0.14
15 Aug 2022 $0.15 $0.00 0.00% 318,277 $0.15 $0.15 $0.14
12 Aug 2022 $0.15 $-0.01 -6.67% 117,004 $0.14 $0.15 $0.14
11 Aug 2022 $0.15 $0.01 6.90% 66,177 $0.15 $0.15 $0.14
10 Aug 2022 $0.15 $-0.01 -6.67% 2,077,354 $0.15 $0.15 $0.15
08 Aug 2022 $0.15 $0.00 0.00% 142,122 $0.15 $0.15 $0.14
04 Aug 2022 $0.15 $0.02 14.81% 74,799 $0.14 $0.15 $0.14
03 Aug 2022 $0.14 $-0.01 -6.90% 177,128 $0.13 $0.15 $0.13
02 Aug 2022 $0.15 $-0.01 -6.67% 222,557 $0.15 $0.15 $0.15
01 Aug 2022 $0.15 $0.00 0.00% 1,641,189 $0.14 $0.15 $0.13
29 Jul 2022 $0.15 $0.01 7.14% 72,029 $0.14 $0.15 $0.14
27 Jul 2022 $0.14 $-0.02 -12.90% 405,358 $0.15 $0.15 $0.14
26 Jul 2022 $0.16 $0.01 6.67% 41,577 $0.15 $0.16 $0.14
25 Jul 2022 $0.15 $-0.02 -12.12% 75,343 $0.15 $0.16 $0.14
22 Jul 2022 $0.17 $0.00 0.00% 52,050 $0.15 $0.17 $0.15
21 Jul 2022 $0.17 $0.01 6.25% 40,876 $0.16 $0.17 $0.16
20 Jul 2022 $0.16 $-0.01 -6.06% 109,007 $0.16 $0.16 $0.15

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
26 Aug 2021 Maria (Mary) Sontrop Sell 275 $175,065
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Alan David Fisher Non-Executive DirectorNon-Executive Chairman Jun 2015
Mr Fisher is experienced corporate advisor and public company director. His main areas of experience include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice. Currently, he is Non-Executive Chair of Centrepoint Alliance Ltd, Non-Executive Director and Chair of Audit and Risk Committees of Bionomics Ltd and Thorney Technologies Ltd, and Non Executive Director of Simavita Ltd. He is a member of the Risk committee.
Mr Michael John Kotsanis Non-Executive Director Mar 2020
Mr Kotsanis over 30 years of strategic and operational experience in the global pharmaceutical industry. Michael was appointed as CEO of Acrux Ltd in November 2014. He was formerly the Chief Commercial Officer and a Board Member of Synthon Holding BV, a Dutch based international pharmaceutical company with revenue over EUR250 million, a position he held for four years. Prior to Synthon, he served as President, Europe, Middle East and Africa, for Hospira. Michael joined Hospira following its acquisition of Mayne Pharma in 2007, where he had served as President, Asia Pacific from 2002. He joined Mayne following their acquisition of FH Faulding in 2001, where he held responsibility for commercial activities of the pharmaceutical business in Australia and New Zealand. Michael was formerly a Board Member of the European Generics Association and a Director of the Generic Medicines Industry of Australia. He is a member of the Risk committee.
Mr Hugh Nigel Burrill Non-Executive Director Oct 2015
Mr Burrill was Corporate Vice President, Global Pharma Research & Development, Hospira Inc where he was responsible for overall pipeline portfolio management, and research and development of generic and specialty pharmaceuticals. Prior to this he held senior international roles within Hospira Inc and the original Mayne Pharma Ltd and currently provides consulting services in pharmaceutical strategic management, product development, regulatory affairs and intellectual property. He is Chair of the Risk committee.
Dr Jane Ryan Non-Executive Director Jan 2022
Dr Ryan has commercial pharmaceuticals background with over 30 years of international experience in the pharmaceutical and biotechnology industries having worked in Australia, US and UK. She has held senior executive roles in management of research and development programs as well as business development and alliance management. Throughout her career, she has led many fundraising campaigns and licensing initiatives including the US Government contract. Jane is currently a Non-Executive Director of Anatara Lifesciences Ltd and Bionomics Ltd.
Dr David Sparling Joint Company SecretaryChief Executive Officer Feb 2018
-
Ms Ancila Desai Chief Financial OfficerJoint Company Secretary Jun 2020
-
Ancila Desai Chief Financial OfficerJoint Company Secretary
-
Paul McDonald Head of Quality and Development
-
David Sparling Joint Company SecretaryChief Executive Officer
-
Jim Sosic Vice President Operations Supply and Infrastructure
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
UBS Nominees Pty Ltd 20,402,924 8.51%
HSBC Custody Nominees (Australia) Limited 19,773,269 8.24%
One Managed Invt Funds Ltd 18,161,934 7.57%
Citicorp Nominees Pty Limited 15,811,239 6.59%
One Fund Services Ltd 8,398,434 3.50%
Brispot Nominees Pty Ltd 8,004,797 3.34%
Mr Anthony John Huntley 7,500,000 3.13%
Graeme Leslie Blackman 7,029,710 2.93%
CS Third Nominees Pty Limited 6,141,162 2.56%
CS Fourth Nominees Pty Limited 5,838,039 2.43%
Jamplat Pty Ltd 5,725,000 2.39%
J P Morgan Nominees Australia Pty Limited 4,786,001 2.00%
I'Rom Group Co Ltd 3,766,035 1.57%
Mr Rodney Bruce Ebsworth 3,750,000 1.56%
Picherit'S Farm Pty Ltd 3,500,000 1.46%
Paulene Blackman 3,457,737 1.44%
David Sparling 2,936,621 1.18%
Goen Investments Pty Ltd 2,500,000 1.04%
Mr Anthony John Huntley (i) 2,500,000 1.04%
Mr Gavin George Rogers & Ms Kathryn Ann Rogers 2,500,000 1.04%

Profile

since

Note